A detailed history of Alps Advisors Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 65,947 shares of ETNB stock, worth $520,981. This represents 0.01% of its overall portfolio holdings.

Number of Shares
65,947
Previous 52,456 25.72%
Holding current value
$520,981
Previous $585,000 31.11%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$8.13 - $13.77 $109,681 - $185,771
13,491 Added 25.72%
65,947 $767,000
Q4 2023

Feb 14, 2024

SELL
$6.66 - $16.03 $21,411 - $51,536
-3,215 Reduced 5.77%
52,456 $585,000
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $31,761 - $40,935
2,109 Added 3.94%
55,671 $859,000
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $286,537 - $446,107
20,250 Added 60.79%
53,562 $1.01 Million
Q1 2023

May 10, 2023

BUY
$10.48 - $16.94 $18,119 - $29,289
1,729 Added 5.47%
33,312 $507,000
Q4 2022

Feb 14, 2023

BUY
$7.81 - $12.73 $246,663 - $402,051
31,583 New
31,583 $402,000
Q2 2022

Aug 11, 2022

SELL
$2.09 - $4.02 $43,944 - $84,524
-21,026 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.45 - $14.99 $8,428 - $36,620
-2,443 Reduced 10.41%
21,026 $79,000
Q4 2021

Feb 09, 2022

SELL
$11.15 - $19.66 $12,755 - $22,491
-1,144 Reduced 4.65%
23,469 $307,000
Q3 2021

Nov 15, 2021

SELL
$14.91 - $21.31 $26,957 - $38,528
-1,808 Reduced 6.84%
24,613 $482,000
Q2 2021

Aug 11, 2021

SELL
$17.42 - $28.0 $166,151 - $267,064
-9,538 Reduced 26.52%
26,421 $494,000
Q1 2021

May 07, 2021

BUY
$20.22 - $26.73 $566 - $748
28 Added 0.08%
35,959 $852,000
Q4 2020

Feb 03, 2021

BUY
$23.16 - $28.08 $832,161 - $1.01 Million
35,931 New
35,931 $876,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $367M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.